Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Other Non Operating Income (2016 - 2022)

Plus Therapeutics has reported Other Non Operating Income over the past 11 years, most recently at $1000.0 for Q1 2022.

  • Quarterly Other Non Operating Income fell 50.0% to $1000.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $3000.0 through Dec 2022, changed N/A year-over-year, with the annual reading at $1000.0 for FY2022, 83.33% down from the prior year.
  • Other Non Operating Income was $1000.0 for Q1 2022 at Plus Therapeutics, down from $2000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $352000.0 in Q1 2018 and troughed at -$204000.0 in Q2 2018.
  • The 4-year median for Other Non Operating Income is $5500.0 (2018), against an average of $41750.0.
  • The largest YoY upside for Other Non Operating Income was 113.33% in 2018 against a maximum downside of 423.81% in 2018.
  • A 4-year view of Other Non Operating Income shows it stood at $23000.0 in 2018, then surged by 547.83% to $149000.0 in 2019, then plummeted by 98.66% to $2000.0 in 2021, then crashed by 50.0% to $1000.0 in 2022.
  • Per Business Quant, the three most recent readings for PSTV's Other Non Operating Income are $1000.0 (Q1 2022), $2000.0 (Q3 2021), and $2000.0 (Q1 2021).